Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug aims to tame dangerous inflammation in kidney patients

NCT ID NCT06362759

Completed Disease control Sponsor: Tourmaline Bio, Inc. Source: ClinicalTrials.gov ↗

Summary

This study tested a new drug, TOUR006, designed to lower a key marker of inflammation (hs-CRP) in people with chronic kidney disease. Researchers wanted to see if giving the drug monthly or quarterly was safe and effective at reducing this inflammation. The goal is to see if controlling inflammation could help manage the long-term risks associated with kidney disease.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Site - 0101

    Birmingham, Alabama, 35209, United States

  • Site - 0102

    Fort Mill, South Carolina, 29707, United States

  • Site - 0103

    Greenville, South Carolina, 29607, United States

  • Site - 0104

    Phoenix, Arizona, 85018, United States

  • Site - 0105

    Houston, Texas, 77043, United States

  • Site - 0106

    Chicago, Illinois, 60655, United States

  • Site - 0107

    San Antonio, Texas, 78212, United States

  • Site - 0108

    Knoxville, Tennessee, 37923, United States

  • Site - 0109

    Manassas, Virginia, 20110, United States

  • Site - 0110

    Charlotte, North Carolina, 28208, United States

  • Site - 0111

    Lampasas, Texas, 76550, United States

  • Site - 0112

    Valencia, California, 91355, United States

  • Site - 0113

    Greenacres City, Florida, 334667, United States

  • Site - 0114

    Council Bluffs, Iowa, 51501, United States

  • Site - 0115

    Morton, Illinois, 61550, United States

  • Site - 0117

    Fargo, North Dakota, 58104, United States

  • Site - 0119

    Port Orange, Florida, 32127, United States

  • Site - 0120

    Cincinnati, Ohio, 45219, United States

  • Site - 0122

    Savannah, Georgia, 31406, United States

  • Site - 0123

    Las Vegas, Nevada, 89121, United States

  • Site - 0125

    San Dimas, California, 91773, United States

  • Site - 0126

    Providence, Rhode Island, 02818, United States

  • Site - 0127

    Marion, Ohio, 43302, United States

  • Site - 0128

    Valencia, California, 91355, United States

  • Site - 0129

    Metairie, Louisiana, 70006, United States

  • Site - 0130

    Middletown, New York, 10940, United States

  • Site - 0132

    Bethlehem, Pennsylvania, 18017, United States

  • Site - 0134

    Kenosha, Wisconsin, 53144, United States

  • Site - 0135

    Huntsville, Alabama, 35763, United States

  • Site - 0136

    Stamford, Connecticut, 06905, United States

  • Site - 0141

    San Antonio, Texas, 78255, United States

  • Site - 0144

    Plantation, Florida, 33317, United States

  • Site - 0145

    Huntsville, Alabama, 35805, United States

  • Site - 0147

    Morgantown, West Virginia, 26505, United States

  • Site - 0148

    Greenville, Texas, 75402, United States

  • Site - 0149

    Pembroke Pines, Florida, 33024, United States

  • Site - 0150

    McKinney, Texas, 75069, United States

  • Site - 0151

    Tampa, Florida, 33634, United States

Conditions

Explore the condition pages connected to this study.

C-REACTIVE PROTEIN CHRONIC KIDNEY DISEASES CHRONIC KIDNEY INSUFFICIENCY CHRONIC RENAL DISEASES CHRONIC RENAL INSUFFICIENCY HIGH SENSITIVITY C-REACTIVE PROTEIN HS-CRP HSCRP KIDNEY INSUFFICIENCY, CHRONIC